As reported previously [12]–[14], the majority of triple transgenic females that overexpressed wildtype ErbB2 developed CK8-positive, luminal-type mammary tumors after a medium latency of more than 6 months in the FVB background (data not shown). This evidence concerns the gene ERBB2 and breast cancer.